PRT2527

targets CDK9 via inhibition

Developed for: acute myeloid leukemia · castration-resistant prostate carcinoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myelomonocytic leukemia · diffuse large B-cell lymphoma · hormone receptor-positive breast cancer · mantle cell lymphoma · marginal zone lymphoma
+5 more
· myelodysplastic syndrome · non-small cell lung carcinoma · Richter transformation · sarcoma · T-cell non-Hodgkin lymphoma
Investigated by: Prelude Therapeutics · BeiGene

today NCT05665530 · Ph 1 NCT05159518 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05665530	Sep 2023 → Jun 2025	Richter transformation, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +5	Prelude Therapeutics	Completed	No outcome recorded
Phase 1	NCT05159518	Feb 2022 → Dec 2023	castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, sarcoma	Prelude Therapeutics	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	PRT2527	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05665530 ↗ 1 NCT05159518 ↗
Action	Inhibit	“a CDK9 inhibitor” NCT05159518 ↗
Route	Intravenous	“PRT2527 will be administered by intravenous infusion” NCT05159518 ↗
Target	CDK9	“a CDK9 inhibitor” NCT05159518 ↗